Impact of KRAS Mutations in Patients with Metastatic CRC Treated with EGFR
Common 7 KRAS mutations in exon 1 (codons 12 and 13) in CRC
Comparison of Methods Used for KRAS Mutation Testing
KRAS testing using pyrosequencing. Pyrograms demonstrate wild-type KRAS gene (upper panel) and mutant KRAS gene (lower panel). Note a mutant “A” peak (arrow) indicating nt38 G>A (Gly13Asp, G13D) at codon 13, exon 1 of the KRAS gene. (Courtesy of Dr Chupong Ittiwut, PhD, Chulalongkorn GenePRO Center, Faculty of Medicine, Chulalongkorn University)
KRAS testing using allele-specific real-time PCR (The DxS TheraScreen KRAS Mutation Kit). (A) Positive for KRAS mutation. Note the second curve (arrow) representing the amplification of a KRAS mutation. (B) Negative for KRAS mutation. Note the curve at cycle 24 (arrowhead) served as internal control (exon 4 of the KRAS gene). (C) The DxS TheraScreen KRAS Mutation Kit analysis report using the LightCycler® Adapt Software v1.1 (Roche Diagnostics, Penzberg, Germany). (Courtesy of Dr. Alisa Junpee, PhD, Bio Molecular and Pathology Laboratory, National Healthcare Systems CO., Ltd)
All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission
from the publisher.